Live data · NADAC + Part D CY24 · reviewed daily

Dulaglutide (TRULICITY)

GLP-1 Receptor Agonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2014-09-18
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$7.87B in CY2024 Part D spend6.2M claims · 1.3M beneficiaries · 329 plans surveyed

Lowest NADAC
$487.42/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$487.51
Across all dosage forms in distribution.
Highest NADAC
$487.57
Range is tight.
Plans with PA
1252 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Dulaglutide used for?

Dulaglutide is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Dulaglutide?

No. Dulaglutide is brand-only with no generic equivalents currently in market.

How much does my plan pay for Dulaglutide?

Across 329 Part D plans, Dulaglutide averages $487.51/unit (NADAC). Lowest available: $487.42/unit. Highest in distribution: $487.57/unit.

Is Dulaglutide on the FDA shortage list?

No. Dulaglutide is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.